Trial · NCT01792635
Outcomes17
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Glucose Infusion Rates (GIR) in Part A | 1 day | All participants randomized and who had at least one euglycemic hyperinsulinemic clamp | mg/min | MEAN |
| PRIMARY | Endogenous Gucose Production (EGP) in Part A | 1 day | All participants randomized and who had at least one euglycemic hyperinsulinemic clamp | mg/kilogram (kg) body weight (BW)/min | MEDIAN |
| PRIMARY | [6,6-2H2] Plasma Glucose Enrichment (PGE) in Part A | 1 day | All participants randomized and who had at least one euglycemic hyperinsulinemic clamp | percentage enrichment of plasma glucose | MEAN |
| PRIMARY | Rate of Appearance of Glucose (Ra) in Part A | 1 day | All participants randomized and who had at least one euglycemic hyperinsulinemic clamp. | mg/kg BW/min | MEAN |
| PRIMARY | Whole-body Glucose Uptake in Part A | 1 day | All participants randomized and who had at least one euglycemic hyperinsulinemic clamp. | mg/kg BW/min | MEAN |
| PRIMARY | Whole-body Glucose Uptake in Part B in Placebo Group | 6 weeks | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | mg/kg BW/min | MEAN |
| PRIMARY | Whole-body Glucose Uptake in Part B in PF-05175157 200 mg BID Group | 6 weeks | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | mg/kg BW/min | MEAN |
| PRIMARY | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs), or Discontinuation Due to Adverse Events (AEs) in Part B | Baseline to follow-up (up to approximately 10 to 14 days after the last study drug administration) | All participants who were admitted to the clinical research unit (CRU) on Day -5 | Participants | NUMBER |
| PRIMARY | Number of Participants With Laboratory Test Abnormalities in Part B | Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration) | All participants who were admitted to the Clinical Research Unit (CRU) on Day -5 | Participants | NUMBER |
| PRIMARY | Number of Participants With Change From Baseline and Absolute Values in Vital Signs Meeting Categorical Summarization Criteria in Part B | Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration) | All participants who were admitted to the CRU on Day -5 | Participants | NUMBER |
| PRIMARY | Number of Participants With Change From Baseline and Absolute Values in Electrocardiogram (ECG) Meeting Categorical Summarisation Criteria in Part B | Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration) | All participants who were admitted to the CRU on Day -5. | Participants | NUMBER |
| SECONDARY | GIR in Part B in Placebo Group | 6 weeks | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | mg/min | MEAN |
| SECONDARY | GIR in Part B in PF-05175157 200 mg BID Group | 6 weeks | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | mg/min | MEAN |
| SECONDARY | EGP in Part B in Placebo Group | 6 weeks | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | mg/kg fat free mass (FFM)/min | MEDIAN |
| SECONDARY | EGP in Part B in PF-05175157 200 mg BID Group | 6 weeks | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | mg/kg fat free mass (FFM)/min | MEDIAN |
| SECONDARY | Ra in Part B in Placebo Group | 6 weeks | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | mg/kg BW/min | MEAN |
| SECONDARY | Ra in Part B in PF-05175157 200 mg BID Group | 6 weeks | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | mg/kg BW/min | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01792635/outcomes